한글목차

눈염증 치료 세계 시장은 2030년까지 11억 달러에 달할 전망

2023년에 8억 2,080만 달러로 추정되는 눈염증 치료 세계 시장은 분석 기간 2023-2030년에 CAGR 4.2%로 성장하고, 2030년에는 11억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 부신피질 스테로이드는 CAGR 5.0%로 성장을 지속하고, 분석 기간 종료 시 4억 3,270만 달러에 달할 것으로 예측됩니다. 면역억제제 부문의 성장률은 분석 기간 동안 CAGR 4.2%로 추정됩니다.

미국 시장은 2억 2,360만 달러로 추정, 중국은 CAGR 8.0%로 성장 예측

미국 눈염증 치료 시장은 2023년 2억 2,360만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2023-2030년간 CAGR 8.0%로 성장을 지속하여 2030년에는 2억 3,560만 달러 규모에 이를 것으로 예측되고 있습니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.4%와 3.2%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 2.3%로 성장할 것으로 예측됩니다.

세계 눈염증 치료 시장 - 주요 동향과 촉진요인 요약

포도막염으로도 알려진 눈염증은 홍채, 섬모체, 맥락막을 포함한 안구의 중간층의 염증을 특징으로 하는 질환입니다. 이 질환은 감염, 자가면역 질환, 외상 등 다양한 원인으로 인해 발생할 수 있으며, 신속하게 치료하지 않으면 시력 저하를 포함한 심각한 합병증을 유발할 수 있습니다. 눈염증 치료의 주요 목적은 염증을 억제하고 통증을 완화하고 조직 손상을 방지하고 정상적인 시력을 회복시키는 것입니다. 일반적인 치료법에는 부신 피질 스테로이드가 있으며 점안, 내복, 주사 등으로 투여합니다. 또한, 자가면역 질환에 의해 염증이 일어나는 경우에는 면역억제제가 사용됩니다. 어떤 치료법을 선택하는지는 근본 원인, 염증의 중증도, 환자별 요인에 따라 다릅니다.

최근 의료 기술의 진보로 눈염증에 대한 치료법이 크게 개선되었습니다. 면역계의 특정 성분을 표적으로 하는 생물학적 제형은 특히 전통적인 치료에 저항성을 나타내는 심각한 포도막염에 대한 효과적인 치료법으로 등장했습니다. 유리체내 주사 및 서방형 임플란트와 같은 약물 전달 시스템의 혁신은 치료의 효능과 편의성을 증가시키고, 투여 횟수를 줄이고, 환자의 컴플라이언스를 향상시킵니다. 또한, 광간섭 단층계(OCT)나 안저 플루오레세인 혈관 조영 등의 화상 진단 기술의 진보에 의해 눈염증의 보다 조기 그리고 정확한 발견이 가능하게 되어, 적시에 적정한 치료 개입을 할 수 있도록(듯이) 되었습니다. 이러한 기술적 진보는 포도막염이 시력 건강에 미치는 장기적인 영향을 줄이는 데 매우 중요합니다.

눈염증 치료 시장의 성장은 포도막염의 유병률 증가, 눈 건강에 대한 의식 증가, 인구 고령화 등 여러 요인으로 인해 발생합니다. 진단 및 치료 방법에 있어서 기술의 진보는 보다 효과적이고 환자 친화적인 선택을 제공함으로써 시장 확대를 뒷받침하고 있습니다. 생물학적 제제 및 고급 약물전달 시스템의 도입으로 치료 성적이 크게 향상되었으며 건강 관리 제공업체들 사이에서 채용이 진행되고 있습니다. 게다가 신흥 시장에서의 헬스케어 지출 증가와 안과의료서비스에 대한 접근의 개선이 대응 가능한 시장을 확대하고 있습니다. 포도막염의 주요 원인인 자가면역 질환의 부담 증가도 눈염증 치료에 대한 수요 증가에 기여합니다. 환자 교육의 강화와 만성 안 질환의 적극적인 관리는 시장 성장을 더욱 강화하고 있습니다. 이러한 추세가 지속되는 동안 눈염증 치료 시장은 포도막염 및 관련 질환의 관리 개선 및 치료 성적 향상을 위한 혁신적인 솔루션을 제공하여 지속적인 성장을 이루는 태세를 갖추고 있습니다.

조사 대상 기업 예(전 86건)

• AffaMed Therapeutics
• Aldeyra Therapeutics
• Alimera Sciences, Inc.
• Bausch Health Companies Inc.
• Cipla Ltd.
• EyePoint Pharmaceuticals, Inc.
• Formosa Pharmaceuticals, Inc.
• Kiora Pharmaceutical
• Kodiak Sciences
• Laboratoires Thea
• Ocular Therapeutix, Inc.
• Oculis Labs
• Rallybio
• Tarsier Pharma
• TearSolutions

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 스페인
• 러시아
• 기타 유럽
• 아시아태평양
• 호주
• 인도
• 한국
• 기타 아시아태평양
• 라틴아메리카
• 아르헨티나
• 브라질
• 멕시코
• 기타 라틴아메리카
• 중동
• 이란
• 이스라엘
• 사우디아라비아
• 아랍에미리트(UAE)
• 기타 중동
• 아프리카

제4장 경쟁

영문목차

Global Ocular Inflammation Treatment Market to Reach US$1.1 Billion by 2030

The global market for Ocular Inflammation Treatment estimated at US$820.8 Million in the year 2023, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2023-2030. Corticosteroids, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$432.7 Million by the end of the analysis period. Growth in the Immunosuppressants segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$223.6 Million While China is Forecast to Grow at 8.0% CAGR

The Ocular Inflammation Treatment market in the U.S. is estimated at US$223.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$235.6 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Ocular Inflammation Treatment Market - Key Trends and Drivers Summarized

Ocular inflammation, also known as uveitis, is a condition characterized by the inflammation of the middle layer of the eye, which includes the iris, ciliary body, and choroid. This condition can result from various causes such as infections, autoimmune disorders, or trauma, and can lead to serious complications including vision loss if not treated promptly. The primary goal of ocular inflammation treatment is to reduce inflammation, alleviate pain, prevent tissue damage, and restore normal vision. Common treatments include corticosteroids, which can be administered as eye drops, oral medications, or injections. Additionally, immunosuppressive agents are used in cases where inflammation is caused by autoimmune conditions. The choice of treatment depends on the underlying cause, severity of the inflammation, and patient-specific factors.

Recent advancements in medical technology have significantly improved the management of ocular inflammation. Biologic agents, which target specific components of the immune system, have emerged as effective treatments for severe cases of uveitis particularly those resistant to conventional therapies. Innovations in drug delivery systems, such as intravitreal injections and sustained-release implants, have enhanced the efficacy and convenience of treatments, reducing the frequency of administration and improving patient compliance. Furthermore, advancements in diagnostic techniques, including imaging technologies like optical coherence tomography (OCT) and fundus fluorescein angiography, have enabled earlier and more accurate detection of ocular inflammation, allowing for timely and targeted therapeutic interventions. These technological strides are pivotal in mitigating the long-term impact of uveitis on vision health.

The growth in the ocular inflammation treatment market is driven by several factors, including the rising prevalence of uveitis, increasing awareness about eye health, and the aging population. Technological advancements in diagnostics and treatment modalities are propelling market expansion by offering more effective and patient-friendly options. The introduction of biologic therapies and advanced drug delivery systems has significantly improved treatment outcomes, driving adoption among healthcare providers. Additionally, increased healthcare expenditure and improved access to eye care services in emerging markets are expanding the addressable market. The growing burden of autoimmune diseases, which are a major cause of uveitis, also contributes to the increased demand for ocular inflammation treatments. Enhanced patient education and proactive management of chronic eye conditions are further supporting market growth. As these trends continue, the ocular inflammation treatment market is poised for sustained growth, offering innovative solutions for better management and outcomes of uveitis and related conditions.

Select Competitors (Total 86 Featured) -

• AffaMed Therapeutics
• Aldeyra Therapeutics
• Alimera Sciences, Inc.
• Bausch Health Companies Inc.
• Cipla Ltd.
• EyePoint Pharmaceuticals, Inc.
• Formosa Pharmaceuticals, Inc.
• Kiora Pharmaceutical
• Kodiak Sciences
• Laboratoires Thea
• Ocular Therapeutix, Inc.
• Oculis Labs
• Rallybio
• Tarsier Pharma
• TearSolutions

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Ocular Inflammation Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Technological Innovations Propel Growth in Ocular Inflammation Treatment Market
  • Increasing Prevalence of Uveitis Drives Demand for Advanced Treatments
  • Rising Awareness About Eye Health Spurs Market Expansion
  • Aging Population Expands Addressable Market Opportunity
  • Advancements in Diagnostic Techniques Strengthen Business Case for Early Detection
  • Introduction of Biologic Therapies Generates Demand for Specialized Treatments
  • Advanced Drug Delivery Systems Propel Market Growth and Patient Compliance
  • Growing Burden of Autoimmune Diseases Drives Adoption of Ocular Inflammation Treatments
  • Improved Healthcare Expenditure in Emerging Markets Expands Market Reach
  • Integration of Imaging Technologies in Diagnosis Accelerates Market Penetration
  • Innovations in Treatment Modalities Propel Technological Advancements
  • Growing Consumer Preference for Minimally Invasive Procedures Spurs Adoption
  • Enhanced Clinical Outcomes Through Real-Time Monitoring Techniques
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Ocular Inflammation Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Ocular Inflammation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Ocular Inflammation Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Immunosuppressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Anti-Infectives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Topical Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Injectables Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Injectables Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Injectables Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• JAPAN
  • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• CHINA
  • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 47: China Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: China 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 50: China Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: China 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• EUROPE
  • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Ocular Inflammation Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Ocular Inflammation Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• FRANCE
  • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 62: France Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: France 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 65: France Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: France 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• GERMANY
  • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: Germany 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: Italy 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 80: UK Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 83: UK Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: UK 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: Spain 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: Spain 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Russia 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Russia 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Rest of Europe 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 103: Rest of Europe 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Ocular Inflammation Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Ocular Inflammation Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 113: Australia Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Australia Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 115: Australia 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 118: Australia 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• INDIA
  • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 119: India Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 120: India Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 121: India 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 122: India Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 124: India 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 125: South Korea Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 126: South Korea Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 127: South Korea 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 130: South Korea 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Rest of Asia-Pacific Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Ocular Inflammation Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Ocular Inflammation Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 145: Latin America 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 146: Argentina Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Argentina Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 148: Argentina 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 151: Argentina 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 152: Brazil Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Brazil Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 154: Brazil 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 157: Brazil 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 158: Mexico Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Mexico Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 160: Mexico 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 163: Mexico 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Rest of Latin America Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 166: Rest of Latin America 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 169: Rest of Latin America 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Ocular Inflammation Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Ocular Inflammation Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 178: Middle East 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 179: Iran Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Iran Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 181: Iran 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 184: Iran 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 185: Israel Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Israel Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 187: Israel 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 190: Israel 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Saudi Arabia Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 193: Saudi Arabia 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 196: Saudi Arabia 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 197: UAE Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 198: UAE Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 199: UAE 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 202: UAE 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Rest of Middle East Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 205: Rest of Middle East 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 208: Rest of Middle East 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
• AFRICA
  • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 209: Africa Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Africa Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 211: Africa 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 214: Africa 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030

IV. COMPETITION